A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
This study will assess potentially predictive markers of efficacy in participants with NSCLC
receiving oral erlotinib (Tarceva) therapy. The anticipated time on study treatment is until
disease progression, unacceptable toxicity or death.